Focus on multiple myeloma
- 1 November 2004
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 6 (5) , 439-444
- https://doi.org/10.1016/j.ccr.2004.10.020
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysisBlood, 2004
- Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myelomaBritish Journal of Haematology, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cellsLeukemia, 2003
- Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemiaCancer, 2003
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994